Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Therapies
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mardi 14 janvier 2020
Doi : 10.1016/j.therap.2019.11.010
Received : 6 November 2019 ;  accepted : 19 November 2019
Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?
 

Jean-François Dhainaut a, , Olivier Blin b, Florence Herry c,

the participants of Giens XXXV Round Table News

Sylvain Benito d, Pascal Bilbault e, Maxime Cauterman f, Florence Favrel-Feuillade g, Stéphanie Fazi-Leblanc h, Caroline Germain i, Clément Goehrs j, Cécile Grosskopf k, Benoit Labarthe g, Philippe Lechat g, Corneliu Malciu l, Pierre Marquet m, Corinne Miceli-Richard n, Olivier Peyret o, Revital Rattenbach p, Edouard de Saint-Exupéry a
a Le Lab Santé Ile-de-France Innovation, Pépinière d’entreprises Paris-Santé-Cochin, 75014 Paris, France 
b Aix Marseille Université, AP-HM, Pharmacologie, CHU La Timone, 13385 Marseille, France 
c Libheros, 75018 Paris, France 
d Exact Cure, 06000 Nice, France 
e Lysarc, CH Lyon Sud, 69495 Pierre-Bénite, France 
f Kry - Livi, 75013 Paris, France 
g AP-HP, DRCI, Hôpital Saint Louis, 75475 Paris, France 
h CHU de Bordeaux, 33400 Talence, France 
i AP-HP, Siège Victoria, 75004 Paris, France 
j Synapse Medicine, 33000 Bordeaux, France 
k Roche, 92650 Boulogne-Billancourt, France 
l Arkhn, 75005 Paris, France 
m CHU de Limoges, Université de Limoges, Inserm, 87042 Limoges, France 
n AP-HP, Hôpital Cochin, 75014 Paris, France 
o CEA-Leti, 38054 Grenoble, France 
p 4P-Pharma, Campus Pasteur Lille, 59000 Lille, France 

Corresponding author. Lab Santé, Pépinière d’entreprises Paris-Santé-Cochin, 29, rue du Faubourg-St-Jacques, 75014 Paris, France.Lab Santé, Pépinière d’entreprises Paris-Santé-Cochin29, rue du Faubourg-St-JacquesParis75014France
Summary

Although France has numerous assets in the realm of health care, such as the excellence of its research teams, the reputation of its healthcare system, and the presence of many startups, all of which are necessary to become a leader in innovation, it also has combined cultural and regulatory barriers that limit the flexibility and efficiency of interactions between companies/startups and public health institutions. Therefore, the aim of the roundtable discussion was to optimize the interface between those businesses and institutions. Several institutions have successfully implemented teams and procedures which aim to facilitate this interface, with regard to assessments of technology, services provided, the transfer of biological material, R&D collaboration, and licensing agreements. However, there is still a notable absence of entrepreneurial culture among hospital and academic research practitioners; their training regarding innovation remains insufficient and business-related value-creation is non-existent in their career evolution. Pharmaceutical companies, and particularly startups, often lack knowledge about hospital environments and their constraints. As a result, the recommendations of the roundtable participants are as follows: (1) promote reciprocal acculturation between public health institutions and startups through multidisciplinary training in innovation, promoting project development and staff recognition within the institution, and improving pharmaceutical companies’ understanding regarding the health care system; (2) provide those involved with means and resources dedicated to innovation by reserving time for innovation at work, securing the status of the staff involved, and aiding in the search for funding; (3) develop and use standard methodologies and tools; and (4) co-design and co-construct innovative health solutions, encouraging the emergence of participatory and interdisciplinary creative spaces. All of these recommendations should help to make the interface between startups/companies and public health institutions more fluid and attractive for those in the health sector.

The full text of this article is available in PDF format.

Keywords : Startup, Spin-off, Health industry, Hospital, University hospital, University, Engineering schools, Living lab



 Articles, analyses and proposals from Giens workshops are those of the authors and do not prejudice the proposition of their parent organization.



© 2019  Société française de pharmacologie et de thérapeutique@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline